Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

Haematologica. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Gene Expression Regulation, Leukemic / drug effects*
  • Humans
  • Induction Chemotherapy
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Receptors, Immunologic / genetics*
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Receptors, Immunologic
  • Thalidomide
  • Lenalidomide